Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ropivacaine for Pain in Epidermolysis Bullosa
NCT03730584Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of ropivacaine in epidermolysis bullosa (EB), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Efficacy on pain of Ropivacaine at the bath entrance at Day 5. Started Feb 2017; status: completed.
02
Drugs
ropivacaine
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT03730584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730584.